Fatigue in Multiple Sclerosis
Conditions
Keywords
Fatigue, Multiple sclerosis, Anodal tDCS, Prefrontal cortex
Brief summary
The available therapeutic strategies for Multiple Sclerosis (MS)-related symptoms are usually faced with limited efficacy and numerous side effects. Patients with MS frequently suffer from fatigue, affective symptoms, and cognitive deficits.
Detailed description
For these reasons, non-invasive brain stimulation (NIBS) techniques, namely transcranial direct current stimulation (tDCS) might be of help in this context. tDCS is a new NIBS technique with a good safety profile, easy implementation, good patients' tolerance and little or no adverse effects. tDCS uses low levels of constant current delivered to specific brain area via sponge electrodes placed on the scalp. tDCS modifies the polarization of the exposed neuronal circuits. Indeed, it modulates the spontaneous neuronal excitability and activity by a tonic depolarization or hyperpolarization of resting membrane potential. Therefore, applying a home-based intervention is of interest in a population suffering from high levels of physical disability prohibiting them from frequently coming to seek care at the hospital
Interventions
PROCEDUREReal left prefrontal tDCS - sham
Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
PROCEDURESham - Real left prefrontal tDCS
Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Intervention model description
During a routine visit in the Department of Neurology for monitoring MS disease, patients undergo a routine neurological exam which will serve later on to check inclusion/exclusion criteria (i.e., this exam will help rating the disability using the Expanded Disability Status Scale that is also routinely performed in all patients with MS). If a patient is interested in this research, the information form will be given to him/her by one of the study investigators (screening visit). Then, after a period of reflection of at least one week after the screening visit, one study investigator will call the patient to inquire about her/his willingness to participate to the study. If the patient agrees to participate in this research, (s)he will be invited for a baseline visit in the Department of Clinical Neurophysiology for inclusion in the study.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Definite MS diagnosis according to the 2017 McDonald criteria * Fatigue since more than 6 months as assessed by fatigue severity scale (FSS\>5) * Age between 18 and 75 years. * Stable pharmacological and physical treatment since at least one month * Affiliation to the social security regimen * Signature of the informed consent * Ability of the patient to understand the instructions for use of the pacemaker to ensure safe use
Exclusion criteria
* Relapses within the last two months * Active medical device implanted * Intracranial metal implants * Craniotomy, cranial trepanation, aneurysm * Uncontrolled epilepsy * Non-weaned alcoholism, sleep debt * Expanded disability status scale ≥ 6.5 * Severe depression based on Beck Depression inventory (BDI\>19) * Daytime sleepiness based on Epworth Sleepiness Scale (ESS\> 11) * Other neurologic and psychiatric diseases * Known pregnancy by the investigator or breastfeeding * Physical or mental incapacity to give informed consent * Participation in another study (exclusion period following a previous study should be ≥ 6 months) * Patients on AME * Patients under legal protection * Prisoners
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tiredness | 12 weeks | Modified Fatigue Impact Scale (MFIS): cognitive (10 items), physical (9 items) and psychosocial fatigue (2 items). It is a shortened version of the Fatigue Impact Scale that contains 21 of the original 40 items. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Depression | 12 weeks | Mood will be assessed by the Hospital Anxiety and Depression Scale (HADS), which is composed of 7 questions that assess anxiety and 7 questions that assess depression. |
| Anxiety | 12 weeks | Mood will be assessed by the Hospital Anxiety and Depression Scale (HADS), which is composed of 7 questions that assess anxiety and 7 questions that assess depression. |
| Alexithymia | before and after each stimulation period (active and simulated) and four weeks later (four weeks after the last stimulation session of each period). | Alexithymia will be assessed using the 20-item Toronto Alexithymia Scale (TAS), which assesses the difficulties in analysing and describing one's own feelings and an externally oriented thinking. |
| MSQOL scale | 12 weeks | Quality of life will be assessed using the MS quality of life questionnaire (MSQOL), which is a multidimensional scale that assess different functions and can yield physical and mental composite scores. |
| Cognitive functions | 12 weeks | Cognitive functions will be assessed using the cognitive domain of the MSQOL, the Reading the Mind in the Eyes Test (RMET) and empathy quotient (EQ), which evaluated social cognition. |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORSamar AYACHE
Clinical Neurophysiology Department
Outcome results
None listed